Premium
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
Author(s) -
Einsele Hermann,
Borghaei Hossein,
Orlowski Robert Z.,
Subklewe Marion,
Roboz Gail J.,
Zugmaier Gerhard,
Kufer Peter,
Iskander Karim,
Kantarjian Hagop M.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32909
Subject(s) - medicine , blinatumomab , cancer research , cancer , chimeric antigen receptor , lymphoma , cd19 , antigen , immunotherapy , oncology , immunology
Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐cell engager) technology is a targeted immuno‐oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor‐specific antigens, allowing off‐the‐shelf immuno‐oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B‐cell non‐Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small‐cell lung cancer). BiTE molecules with an extended half‐life relative to the canonical BiTE molecules are also being developed. Advances in immuno‐oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.